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OBJECTIVES We examined the effect of long-term treatment with two doses of the angiotensin converting
enzyme (ACE) inhibitor enalapril on various immunological variables in patients with
chronic congestive heart failure (CHF).
BACKGROUND Immunological mediators are increasingly recognized to play a pathogenic role in the
pathophysiology of CHF. Whether ACE inhibitor therapy modifies immunological variables
has not previously been investigated.
METHODS Seventy-five patients (mean age 52 6 11 years) with CHF were randomized between low-
(5 mg daily) and high-dose (40 mg daily) enalapril in a double-blind trial. Circulating levels
of immunological parameters (i.e., proinflammatory cytokines, chemokines and adhesion
molecules) were measured at baseline, at 10 weeks and at the end of the study (34 weeks).
RESULTS All immunological parameters, except soluble interleukin (IL)-6 receptor, were increased in
CHF compared with 21 healthy controls. During the study immunoreactive IL-6 levels
decreased (p , 0.05) and soluble IL-6 receptor increased (p , 0.05) during high-dose but not
during low-dose enalapril therapy. Furthermore, IL-6 bioactivity decreased only during the
high-dose (p , 0.001), resulting in a significant difference in change during treatment
between the two dosage groups (p , 0.001). This decrease in IL-6 bioactivity was
significantly associated with decreased interventricular septum thickness as assessed by
echocardiography (r 5 0.56, p 5 0.013). No other variables changed during treatment.
CONCLUSIONS In patients with severe CHF, high-dose enalapril therapy is associated with a significant
decrease in IL-6 activity. However, despite treatment with a high-dose ACE inhibitor, a
persistent immune activation exists in these patients which may be of importance for the
progression of CHF. (J Am Coll Cardiol 1999;34:2061–7) © 1999 by the American College
of Cardiology
Immune mediated mechanisms have recently been recog-
nized to play an important role in the pathophysiology of a
number of cardiac disorders. Enhanced immune activation
has not only been found in acute disorders such as myocar-
ditis (1) but also in chronic conditions such as congestive
heart failure (CHF), reflected in increased circulating levels
of various proinflammatory cytokines (i.e., tumor necrosis
factor [TNF alpha], interleukin [IL]-1 and IL-6) (2–5). We
have recently also demonstrated elevated circulating levels of
C-C chemokines (C-C subfamily of chemokine superfam-
ily) and various soluble adhesion molecules in chronic CHF
(6,7), further indicating that immune activation is a distinct
feature of this disorder.
The precise pathophysiological importance of these im-
munological variables is at present unclear. However, TNF
alpha appears to mediate negative inotropic effects on the
See page 2068
myocardium by various mechanisms (8–10). Furthermore,
IL-6 and related cytokines have been implicated in the
development of ventricular hypertrophy through enhanced
stimulation of their common gp130 receptor subunit ex-
pressed on cardiac myocytes (11). Less is known about the
pathophysiological role of chemokines in CHF, but we have
recently demonstrated that the C-C chemokine monocyte
chemoattractant peptide-1 (MCP-1) may have a direct role
in the induction of oxidative stress in this disorder (6).
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Moreover, the levels of circulating adhesion molecules
appear to reflect the expression and shedding of adhesion
molecules on the surface of various cells (12), and these
molecules may be of importance for the inflammatory
response in the vessel wall and the myocardium (12). Thus,
it is tempting to hypothesize that modulation of immuno-
logical variables could be of importance for disease progres-
sion, possibly being a therapeutic goal in the treatment of
CHF.
So far there are few reports on the effects of various
cardiovascular treatment regimens on cytokine levels in
CHF. In vitro studies have demonstrated that the positive
inotropic agents ouabain and vesnarinone can modulate the
production of proinflammatory cytokines in mononuclear
cells from patients with heart failure (13,14), and the
calcium antagonist amlodipine appears to decrease plasma
levels of immunoreactive IL-6 in patients with CHF (15).
However, for the angiotensin converting enzyme (ACE)
inhibitors there are no reports on how they influence
cytokine levels in vivo.
The ACE inhibitors have become a cornerstone in the
treatment of CHF with favorable effects on mortality and
morbidity (16), but the precise mode of action is not known.
In this study we examined the effect of two doses of the
ACE inhibitor enalapril on various immunological variables
in 75 patients with CHF for a period of 34 weeks.
Angiotensin converting enzyme inhibition has also been
found to reverse ventricular hypertrophy (17), and it was of
particular interest to see if enalapril could modulate IL-6
activity, as this cytokine appears to be involved in the
development of cardiac hypertrophy (11).
METHODS
Patients and controls. The study population which previ-
ously has been reported (18) consisted of 75 patients (61
men and 14 women; mean age 52 6 11 years) with chronic
symptomatic heart failure for more than three months in
New York Heart Association functional class II–IV and
with left ventricular ejection fraction ,40% (Table 1). Their
clinical and hemodynamical situations were stable with no
evidence of myocardial infarction in the last three months
and no change in medication in the last month. Before the
study all the patients were treated with low-dose ACE
inhibitors. Other standard medical treatment consisted of
diuretics (100%) and digoxin (79%). Patients with signifi-
cant concomitant disease such as acute and chronic infec-
tions, pulmonary disease, malignancy or collagen vascular
disease were not included.
Control subjects were 21 gender- and age-matched
healthy blood donors (16 men and 5 women; 25 to 69 years,
mean 52 years) without any history of cardiac disease.
Study design. The study design has previously been de-
scribed (18). Briefly, 86 patients entered into open labelled
treatment with a low-dose of enalapril, 2.5 mg b.i.d for two
weeks. During this time period, 11 withdrew (four because
of adverse clinical experience; two had intolerance to ena-
lapril, two unable to comply with study drug, two had other
reasons and one patient died). The study group therefore
consisted of 75 patients who were randomized between low-
(5 mg daily) and high doses (40 mg daily) of enalapril in a
double blind fashion. The dose was gradually increased
during 8 weeks and the patients were followed for an
additional 26 weeks.
Blood sampling protocol. Blood was collected from an
antecubital vein at baseline after 10 weeks and at termina-
tion of the study (34 weeks) into pyrogen-free vacuum blood
collection tubes (Becton Dickinson, San Jose, California)
without any additives (serum) or with EDTA as anticoag-
ulant (plasma). Tubes were immediately immersed in melt-
ing ice and centrifuged within 15 min at 1,000 g and 4°C for
15 min (plasma) or allowed to clot for 1 h before centrifu-
gation at 1,000 g in 10 min (serum). Both serum and plasma
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
CHF 5 congestive heart failure
CONSENSUS 5 Cooperative North Scandinavian
Enalapril Survival Study
EIA 5 enzyme immunoassays
IL 5 interleukin
IVS 5 interventricular septum thickness
MCP-1 5 monocyte chemoattractant peptide-1
s 5 soluble
sIL-6R 5 soluble interleukin-6 receptor
TNF alpha 5 Tumor necrosis factor alpha
Table 1. Clinical Characteristics of the CHF Patients
Participating in the Low-Dose (5 mg/day) Versus High-Dose
(40 mg/day) Enalapril Study
Low-Dose
n 5 38
High-Dose
n 5 37
Age (yrs) 51 6 12 52 6 11
Gender (men/women) 33/5 28/9
Cause of heart failure
CAD 15 (40%) 22 (60%)
IDCM 17 (45%) 9 (24%)
Other 6 (15%) 6 (16%)
Duration of heart failure
(months)
41 6 54 34 6 42
LV ejection fraction (%) 21 6 9 21 6 7
Peak VO2 (ml/kg/min) 15.7 6 4.9 17.0 6 5.4
Medication (%)
ACE inhibitors 100 100
Diuretics 100 100
Digoxin 82 81
ACE 5 angiotensin converting enzyme; CAD 5 coronary artery disease; IDCM 5
idiopathic dilated cardiomyopathy; LV 5 left ventricle.
Data are given as mean 6 SD.
2062 Gullestad et al. JACC Vol. 34, No. 7, 1999
Cytokines and Enalapril in CHF December 1999:2061–7
were stored at 280°C in multiple aliquots until analysis.
Samples were thawed only once.
Enzyme immunoassays (EIAs). TNF alpha (detection
limit 3.0 pg/ml) levels in plasma were measured by EIAs
(Medgenix, Fleurus, Belgium) as previously described (19)
using microtiter wells coated with several monoclonal anti-
bodies against distinct epitopes of the TNF alpha molecule.
Plasma levels of IL-1 receptor antagonist (IL-1Ra, detec-
tion limit 22.0 pg/ml), IL-6 (detection limit 0.70 pg/ml),
soluble (s) IL-6 receptor (sIL-6R (detection limit 3.5 pg/ml),
MCP-1 (detection limit 8 pg/ml), sP-selectin (detection
limit 0.5 ng/ml) and soluble vascular adhesion molecule-1
(VCAM-1, detection limit 2 ng/ml) were measured by
EIAs according to the manufacturer’s instruction (R&D
Systems, Minneapolis, Minnesota). Plasma levels of IL-
1beta (detection limit 0.1 pg/ml) were determined by a high
sensitivity EIA as recommended by the manufacturer
(R&D Systems). Plasma levels of soluble TNF receptors
(sTNFRs), p55 and p75, were analyzed by EIAs (detection
limit between 150–300 pg/ml) as described by Liabakk et
al. (20). The intra- and interassay coefficients of variation
were less than 10% for all EIAs.
IL-6 bioassay. Serum levels of IL-6 bioactivity were
determined by the IL-6 dependent mouse hybridoma cell
line B13.29 assay (21) at baseline and at the end of the
study in all but 11 patients. The sensitivity of the assay
was 4 pg/ml.
Measurements of neopterin. Plasma levels of neopterin
were determined by radioimmunoassay (IMMU test Neop-
terin, Henning Berlin GMBH, Berlin, Germany).
Echocardiography. Studies were performed by an expe-
rienced sonographer and were interpreted by a single
cardiologist. Echocardiography was performed with the
use of a Hewlett-Packard (Hewlett-Packard Co., Medi-
cal Products Group) ULS machine, 2.5 or 3.5 mHz,
combined imaging and Doppler transducer. Each patient
was studied in the left lateral decubitus position after
15 min of recumbency.
Statistical analyses. The SPSS (SPSS Inc., Chicago, Illi-
nois) statistical package was used for statistical analysis.
Differences between groups were compared with Mann-
Whitney U Rank-Sum test for unpaired data. In the paired
situation, multiple analysis of variance (MANOVA) were
performed priori and, if significant, Wilcoxon’s Rank-Sum
test for paired data was performed a posteriori. Relations
between variables were tested using Spearman’s Rank-
Correlation test. Data are given as medians and 25th to 75th
percentiles if not otherwise stated. P values are two-sided
and considered significant when ,0.05. Particular attention
should, however, be directed toward small p values, i.e.,
those below 0.01, because a considerable number of p values
have been calculated.
RESULTS
The clinical characteristics of the two treatment groups are
given in Table 1. The two groups were similar with respect
to key demographic and clinical signs of CHF. Twenty-five
patients (14 in the low-dose and 11 in the high-dose group)
withdrew during treatment (9 due to adverse clinical expe-
rience, 6 were transplanted, 5 died, 2 due to protocol
violation and 3 for other reasons).
Circulating levels of proinflammatory cytokines and their
endogenous modulators during therapy. At baseline
plasma levels of IL-1beta, IL-6 and TNF alpha as well as
IL-1Ra and both types of sTNFRs (p55 and p75), but not
sIL-6R, were markedly elevated among CHF patients
compared with healthy control subjects (Table 2).
While IL-6 and sIL-6R remained unchanged during
treatment with low-dose enalapril, high-dose therapy
caused a significant decrease in IL-6 and an increase in
sIL-6R levels (Table 2). However, the difference in changes
during treatment between the two regimens was not statis-
tically significant (p 5 0.3).
In contrast to the fall in IL-6 and rise in sIL-6R, plasma
levels of TNF alpha and IL-1beta as well as sTNFRs and
IL-1Ra did not change during enalapril therapy in either
dosage groups.
Chemokines, soluble adhesion molecules and neopterin.
Plasma levels of MCP-1, a member of the C-C chemokine
family, the soluble adhesion molecules sVCAM-1 and
sP-selectin and levels of neopterin, known to be a nonspe-
cific marker of monocyte/macrophage activity (22), were all
significantly increased at baseline compared with healthy
controls but remained unchanged during therapy irrespec-
tive of the enalapril dosage (Table 2).
IL-6 bioactivity. Our findings suggest that the persistent
immune activation in CHF patients is not modulated by
enalapril treatment in either dosage group, except for a
decrease in IL-6 and a rise in sIL-6R levels during high-
dose therapy. In contrast to other soluble cytokine receptors,
sIL-6R has an agonistic effect on IL-6 activity (23,24). To
investigate the biological significance of decreased IL-6 and
increased sIL-6R levels during enalapril therapy, we there-
fore measured IL-6 bioactivity before and at the end of
enalapril treatment. As can be seen in Figure 1, IL-6
bioactivity significantly decreased from 7.5 (5.4 to 10) pg/ml
to 4.4 (4.3 to 6.2) pg/ml (p , 0.001) during high-dose
therapy while no change was observed during low-dose
treatment (4.8 [4.3 to 7.5] pg/ml to 4.6 [4.3 to 7.3] pg/ml).
Furthermore, there was a significant difference in changes
observed during treatment between the two enalapril dosage
groups (Fig. 1, p , 0.001). In fact, during high-dose
enalapril, 28 patients had a decrease in IL-6 bioactivity
while only three and one had no change or an increase in
IL-6 bioactivity, respectively. Thus, during high-dose ena-
lapril therapy in CHF patients, there is a significant de-
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crease in IL-6 levels as measured by both immuno- and
bioassays, and as for IL-6 bioactivity, the response to
enalapril was significantly different between the two dosage
groups.
There was a tendency for a positive correlation between
changes in IL-6 bioactivity and immunoreactive IL-6 (r 5
0.32, p 5 0.66) but not between IL-6 bioactivity and
sIL-6R (r 5 20.08, ns). At baseline there was a slight but
significant difference in IL-6 bioactivity between high- and
low-dose enalapril with the highest levels in the high dose
group (Fig. 1). However, in this latter group both patients
with high and low baseline levels demonstrated a significant
decrease in IL-6 bioactivity (data not shown).
Association between IL-6 levels and reduction in left
ventricular hypertrophy. Interleukin-6 has been suggested
to play a role in the development of cardiac hypertrophy
(11). We therefore next looked at the association between
changes in IL-6 levels and indexes of left ventricular wall
thickness as assessed by echocardiography (18). While
posterior wall thickness remained unchanged, interventric-
ular septum thickness (IVS) decreased significantly from
1.01 to 0.91 cm (p , 0.05) during high-dose treatment
while no change was observed during the low dose (Table
3). In the high-dose enalapril group there was a significant
positive correlation between changes in IL-6 bioactivity and
IVS (r 5 0.56, p 5 0.013, Fig. 2), while no such relation-
ship was found during low-dose treatment (r 5 20.23, p 5
0.31).
DISCUSSION
In this study we demonstrate for the first time that ACE
inhibitor therapy decreased IL-6 activity in circulation in
CHF patients as measured by both immuno- and bioassay.
The decrease in IL-6 activity was only observed with a high
dose of ACE inhibition and as for IL-6 bioactivity the
response to enalapril was significantly different between the
two dosage groups, supporting previous studies suggesting
that high-dose ACE inhibition is superior to low dose with
regard to clinical effects (25). Furthermore, although there
was a decrease in circulating IL-6 levels, even high-dose
long-term treatment with enalapril did not normalize IL-6
levels and, more importantly, such therapy appears not to
decrease the levels of other immunological parameters
reflecting persistent immune activation in CHF.
Table 2. Plasma Levels of Immunological Variables at Baseline, at 10 Weeks and at End of
Study (34 weeks) After Treatment With Low (LD, 5 mg/day) or High (HD, 40 mg/day) Dose
of Enalapril
Baseline 10 Weeks
LD HD LD HD
IL-6 (pg/ml) 3.2 (1.8–6.9) 2.2 (1.0–3.8) 2.5 (1.0–3.5) 1.6 (1.0–2.7)§
sIL-6R (ng/ml) 30 (25–37) 30 (24–40) 30 (25–38) 33 (24–39)§
TNF alpha (pg/ml) 15 (11–22) 16 (10–19) 14 (10–19) 17 (11–22)
p55-TNFR (ng/ml) 2.1 (1.8–2.7) 2.0 (1.7–2.4) 2 (1.7–2.8) 1.9 (1.7–2.4)
p75-TNFR (ng/ml) 3.5 (2.6–4.2) 3.2 (2.5–3.8) 3.7 (2.4–4.5) 3.1 (2.6–3.7)
IL-1beta (pg/ml) 0.4 (0.2–0.9) 0.4 (0.2–0.9) 0.3 (0.1–0.7) 0.3 (0.1–0.8)
IL-1Ra (pg/ml) 153 (80–254) 140 (82–243) 121 (71–247) 93 (63–160)
sVCAM-1 (ng/ml) 688 (547–911) 633 (520–851) 671 (555–893) 629 (532–841)
sP-select (ng/ml) 68 (59–87) 75 (60–83) 73 (59–87) 74 (61–89)
MCP-1 (pg/ml) 202 (167–242) 190 (155–234) 187 (157–219) 187 (159–254)
Neopterin (mmol/l) 23 (22–24) 23 (22–24) 23 (22–24) 23 (22–24)
End of Study
ControlLD HD
IL-6 2.7 (1.0–2.6) 1.0 (1.0–2.6)§ 1.0 (1.0–1.1)‡
sIL-6R 27 (24–34) 33 (27–40)§ 33 (29–37)
TNFalpha 15 (10–22) 16 (12–23) 3 (3–5)‡
p55-TNFR 1.9 (1.7–2.3) 2.0 (1.5–2.2) 1.1 (1.0–1.2)‡
p75-TNFR 3.6 (2.7–4.6) 3.1 (2.8–3.4) 2.6 (2.3–2.9)†
IL-1 beta 0.4 (0.2–0.9) 0.4 (0.3–0.9) 0.3 (0.1–0.5)*
IL-1Ra 134 (67–210) 119 (69–178) 112 (45–143)*
sVCAM-1 652 (593–813) 627 (538–737) 391 (362–491)‡
sP-select 74 (54–91) 71 (61–94) 55 (46–68)‡
MCP-1 185 (161–218) 190 (152–238) 115 (77–127)‡
Neopterin 23 (22–24) 23 (22–23) 7 (5–9)‡
Except for neopterin which was measured by radioimmunoassay, all immunological parameters were analyzed by enzyme
immunoassay. Data are given as median and 25th–75th percentiles.
*p , 0.05, †p , 0.01, ‡p , 0.001: heart failure versus controls. §p , 0.05 versus baseline.
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Effect of cardiovascular therapy on cytokine levels.
There has recently been a growing interest in the contribu-
tion of cytokine activation in the pathophysiology of chronic
CHF with its possible effect on myocardial contractility and
remodeling (26), and the concept of immunomodulatory
therapy has emerged as an option (27). There are, however,
few data on how traditional medications used in this
condition influence relevant cytokine levels in humans. A
recent study with the dihydropyridine calcium channel
blocker, amlodipine, demonstrated an improvement in ex-
ercise time which was associated with a reduction in serum
neopterin levels (28) and a reduction in levels of immuno-
reactive IL-6 has been suggested to be of importance for the
beneficial effect of this agent on mortality in patients with
idiopathic dilated cardiomyopathy (15). As for the ACE
inhibitors, no data have so far been available.
Effect of enalapril on the persistent immune activation in
CHF. Except for a favorable effect on the IL-6 system, all
of the other immunological parameters measured were
markedly elevated in CHF patients and remained un-
changed during treatment with either dose of enalapril. Our
results therefore confirm the findings from several cross-
sectional observations demonstrating elevated circulating
levels of various proinflammatory cytokines in CHF (2–5).
However, there are very few longitudinal studies of cytokine
levels in CHF, and this study demonstrated that the
elevation of several immunological parameters in CHF
patients persists during longitudinal testing and during
optimal cardiovascular therapy including high-dose ACE
inhibitors. The pathophysiological importance of this find-
ing remains to be determined, but several of the immuno-
logical parameters studied may impair cardiac function, e.g.,
TNF alpha, IL-1 and MCP-1 (6,8,9,29–31). One might
speculate that this persistent immune activity contributes to
the high mortality and the continuous left ventricular
remodeling in this patient group despite intensive treatment
with ACE inhibitors in addition to optimal standard CHF
medication (32).
Effect of enalapril therapy on IL-6. In contrast to the
persistent elevation of the other immunological variables,
we found a significant reduction in circulating IL-6 levels
during high-dose ACE inhibitor therapy as evaluated by
both immuno- and bioassay. The human IL-6 gene is
Figure 1. Plasma levels of IL-6 bioactivity in CHF patients during
therapy with low dose (5 mg/daily) and high dose (40 mg/daily) of
enalapril at baseline and at end of study. The upper panel (A)
shows the absolute concentrations of IL-6 bioactivity during
therapy. ***p , 0.001 versus baseline. The lower panel (B) shows
the changes in IL-6 bioactivity during therapy (concentration at
the end of study—baseline levels). #p , 0.001 versus low-dose
group. Data in box plots are given as medians, 25th–75th percen-
tiles and ranges.
Figure 2. Correlation between change in levels of IL-6 bioactivity
and change in interventricular septum thickness (IVS) measured by
echocardiography during treatment with high-dose enalapril.
Table 3. Echocardiographic Characteristics of the CHF Patients
Participating in the Low-Dose (5 mg/day) Versus High-Dose
(40 mg/day) Enalapril Study
Baseline
Mean
End of
Study Mean
Change From
Baseline
(mean [SD])
LV ED (cm) Low 7.1 7.3 0.1 (0.6)
High 7.1 6.9 20.2 (1.1)
LV ES (cm) Low 6.1 6.1 20.0 (0.6)
High 6.2 5.9 20.1 (0.8)
IVS (cm) Low 0.98 0.99 20.01 (0.23)
High 1.01 0.91 20.12 (0.25)*
LVPW (cm) Low 1.01 1.02 0.02 (0.27)
High 1.02 0.99 20.08 (0.20)
LV EF (%) Low 24.4 27.1 3.6 (8.5)
High 21.0 26.3 3.6 (12.8)
LV ED and LV ES 5 left ventricular end diastolic and systolic dimensions,
respectively; IVS 5 interventricular septum thickness; LVPW 5 left ventricular
posterior wall thickness; LV EF 5 left ventricular ejection fraction.
*p , 0.05 versus baseline.
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transcriptionally inducible in several different cell types in
response to various inflammatory cytokines such as IL-1
and TNF alpha (23,24). However, in this study there was no
reduction in levels of either of these cytokines, possibly
suggesting a selective decrease in IL-6 activity during
enalapril therapy in CHF. Interestingly, it has recently been
shown that ACE inhibition as well as angiotensin II
receptor type I antagonist may decrease the activation of
NFkappaB at least partly involving redox-sensitive signaling
events (33,34), and such a mechanism may also possibly be
involved in the IL-6 inhibitory effect of enalapril. However,
we found no effect of ACE inhibition on other cytokines
known to be influenced by NFKappaB activation (e.g.
MCP-1 and TNF alpha), and the mechanism for the
selective decrease in IL-6 levels during ACE inhibitor
treatment remains unclear.
Reduction in ventricular hypertrophy during enalapril
therapy—a consequence of decreased IL-6 levels? What-
ever the reason, this reduction in IL-6 activity may be of
clinical importance. Angiotensin converting enzyme inhib-
itor therapy is known to reduce ventricular hypertrophy, but
the mechanisms for this effect have not been clarified.
Several studies in animal models demonstrate that IL-6 and
related cytokines (e.g., leukemia inhibitory factor and
cardiotrophin-1), through stimulation of their common
receptor subunit gp130 in cardiomyocytes, are potent in-
ducers of cardiac hypertrophy (11,35). It may well be that
the reducing effect of ACE inhibition on cardiac hypertro-
phy at least partly is mediated by reduction of IL-6 levels. In
this study the fall in levels of IL-6 bioactivity and the
reduction of IVS was positively correlated, further support-
ing such a notion. Interestingly, ACE inhibition was re-
cently found to inhibit the stimulatory effect of IL-6 (36),
possibly by interfering with the JAK/STAT pathway
(11,37). Thus, it is possible that an important “antihyper-
trophic” mechanism of ACE inhibitors on human myocar-
dium may be a reduction in IL-6 levels possibly combined
with an impairment of the IL-6 signal transduction.
Study limitations. A limitation of this study is that all
patients were treated with low-dose ACE inhibitors at the
time of baseline blood sampling, and we do not know the
effect of enalapril on “ACE inhibitor naive” patients. Pre-
liminary results from the Cooperative North Scandinavian
Enalapril Survival Study (CONSENSUS) I trial demon-
strated that enalapril did not modify plasma levels of TNF
alpha, neopterin or prostaglandin E2 after six weeks in
severe CHF (38). Thus, in the CONSENSUS trial, the
effect of enalapril on hormonal levels seems to be dissociated
from its effect on cytokines (16), which was also the case in
this study (18). Whether this is also the case in milder form
of CHF remains to be determined.
Another major limitation of this study was the lack of any
placebo group. Although only IL-6 levels were found to
decline during high-dose therapy, we cannot exclude that
ACE inhibition may have some effects on levels of other
cytokines measured. It is possible that the “natural history”
of cytokine levels in CHF patients without ACE inhibition
is a gradual increase as is the case for neurohormones (39).
However, a major point in this study was that whatever the
degree of immune activation that might exist without ACE
inhibition, a high degree of immune activation persisted
even during long-term high-dose ACE inhibition.
Another important question is whether the fall in IL-6
activity represents a true biological effect or simply reflects a
statistically significant finding by chance. We believe that
our observations represent a biological effect of enalapril
therapy. First of all, the fall in immunoreactive IL-6 was not
the only effect of high-dose enalapril, but was associated
with an increase in sIL-6R and a decrease in IL-6 bioac-
tivity. Moreover the changes were already observed after 10
weeks of therapy.
Conclusions. This study supports the notion that high-
dose ACE inhibitor therapy is superior to a low-dose
therapy in the management of CHF patients. During
high-dose enalapril there was a marked decrease in IL-6
activity in the circulation, and this decrease in IL-6 levels
might be of importance for the reduction of ventricular
hypertrophy seen during such therapy. However, despite
“optimal” treatment of CHF, including a high dose of ACE
inhibitor, a high degree of immune activation seems to
persist. More specific immunomodulating treatment modal-
ities therapy may be warranted in management of CHF
patients.
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